Future studies employing pharmacological inhibition or genetic deletion of β3 adrenergic receptor (ADRB3) in adipose tissue to block lipid mobilization could be valuable to better understand the inter-organ signaling during MASLD progression.62 Here, ADRB3 is linked to metabolic dysfunction-associated steatotic liver disease.